Patents making new AIDS drugs expensive, MSF says

New potentially life-saving HIV drugs are "beyond reach" due to restrictive patents, Doctors Without Borders (MSF) said Tuesday, even though basic medication for the disease has become cheaper.

The international medical humanitarian organisation said it was good news that the price of drugs used as first- and second-line treatments had fallen by 19 and 28 percent respectively since last year.

But "salvage regimens"—drugs used as a last resort after these first two steps fail—cost 15 times as much as first-line medicines, according to an MSF statement at the International AIDS Society conference in the Malaysian capital.

"Patents keep them priced beyond reach. We need to watch carefully as newer, better medicines reach the market in the coming years, as these are the drugs that we'll quickly be needing to roll out. The price question is far from resolved," said Jennifer Cohn, medical director at MSF's Access Campaign.

According to MSF, first-line treatment—which has the highest efficacy against a low side-effect profile—can cost as little as $139 per person per year, down from $172.

It cited as the main factor in the price drop, which had also made second-line drugs available for as low as $303 per year.

But MSF said its research found the best price for a possible salvage regimen was $2,006 per year in the , while some like Armenia pay $13,213 just for one of the three or four drugs needed for a full regimen.

"Scaling up HIV treatment and sustaining people on treatment for life will depend on bringing the price of newer drugs down," said Arax Bozadjian, HIV at MSF's Access Campaign.

The group called for wider "patent opposition", claiming that a seven-year battle against Swiss Novartis, was key to falling prices of first- and second-line regimens. Novartis were finally refused a patent this April in generics-producing India.

"When patents prevent access, compulsory licences should be issued (to other drugmakers) in the interest of public health," it added.

The United Nations says 34 million people globally were living with HIV in 2011, with 2.5 million people newly infected that year alone.

In total, the global pandemic has claimed 30 million lives.

add to favorites email to friend print save as pdf

Related Stories

Measles epidemic sweeps northern Syria

Jun 18, 2013

An epidemic of measles is sweeping through parts of northern Syria, with at least 7,000 people affected because the ongoing civil war has disrupted vaccination programmes, Doctors Without Borders said on Tuesday.

Recommended for you

New study reveals why some people may be immune to HIV-1

Nov 20, 2014

Doctors have long been mystified as to why HIV-1 rapidly sickens some individuals, while in others the virus has difficulties gaining a foothold. Now, a study of genetic variation in HIV-1 and in the cells ...

Virus discovery could impact HIV drug research

Nov 20, 2014

A research team led by Portland State University (PSU) biology professor Ken Stedman has unlocked the structure of an unusual virus that lives in volcanic hot springs. The discovery could pave the way for better drugs to ...

UN warns over threat of AIDS rebound

Nov 19, 2014

South African actress Charlize Theron threw her weight Tuesday behind an urgent new UN campaign to end AIDS as a global health threat by 2030.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Sinister1811
1 / 5 (2) Jul 02, 2013
It's a money grubbing system! I am disappointed that in today's world, its all about making money from people's sicknesses and ailments, rather than restoring human health and changing lives. And can you believe they wanted to patent genes too?
jmatulonis
not rated yet Jul 02, 2013
Yup this government is corrupt.
The CDC /IDSA receives kickbacks from Lyme disease testing companies.
Keep people sick and there pockets stay full..

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.